←
Dr Sofia Merajver, MS, MD, PhD ☮️15,187 posts
Dr Sofia Merajver, MS, MD, PhD ☮️ avatar

Dr Sofia Merajver, MS, MD, PhD ☮️

@sofiamerajver

Physician scientist at the University of Michigan. Opinions are my own. Professor of Internal Medicine and Epidemiology. she/her/hers

◷ Joined March 2013▧ 113 Photos and videos
OncLive.com avatar
⟳ Dr Sofia Merajver, MS, MD, PhD ☮️ retweeted
OncLive.com@OncLive·Feb 8

LISTEN 🎧: In our latest episode of #HowThisIsBuildingMe, @DRCamidge and @sofiamerajver discuss her lifelong journey shaped by immigration, intellectual curiosity, and a commitment to science in service of human health. #oncology Click the link to hear her story 🔗▶️: onclive.com/view/how-physics…

Dr Sofia Merajver, MS, MD, PhD ☮️ avatar
Dr Sofia Merajver, MS, MD, PhD ☮️@sofiamerajver·8 Aug 2025

Amazing but not enough! We want much more! Working on it every day is the only way. @UMRogelCancer so that’s what we do. Judith Tam ALK Kung Cancer Research Initiative rogelcancercenter.org/judith…

They’ve lived 10+ years with ALK-positive cancer. That shouldn’t be rare—it should be the norm. This #MakeAWillMonth, create a legacy that fuels research, hope & a future for all ALK+ patients. Make your will free with @FreeWill ⬇️ 👉 freewill.com/alkpositiveinc?…

Post attachment
Dr Sofia Merajver, MS, MD, PhD ☮️ avatar
Dr Sofia Merajver, MS, MD, PhD ☮️@sofiamerajver·28 Apr 2025

Real progress towards understanding the actual metastasis potential cells in ALK+ LC. DNA is only a surrogate. Only live cells can kill patients. Let’s understand them much better and what drives them and let’s kill them. @UMRogelCancer

Mesenchymal (vimentin+) circulating tumor cells (#CTCs) may be progostic for progression in ALK+ #NSCLC. Great to see more non-invasive tests for progression. Collaboration between @NagrathSunitha Dr. Yuru Chen & Dr. Angel Qin @UMRogelCancer #AACR25 @ALKPositiveinc

Post attachmentPost attachmentPost attachment
Yvonne Diaz avatar
⟳ Dr Sofia Merajver, MS, MD, PhD ☮️ retweeted
Yvonne Diaz@Yvonne_Diaz_·18 Apr 2025

This is a truly exciting potential option for ALK once other options exhausted. Love the aim of repurposing drugs which can help get patients the treatments they need faster.

ALK Positive avatar
⟳ Dr Sofia Merajver, MS, MD, PhD ☮️ retweeted
ALK Positive@ALKPositiveinc·17 Apr 2025

What if a leukemia drug could help treat ALK+ lung cancer? A new trial at @UMRogelCancerCtr is exploring gilteritinib—FDA-approved for leukemia—as a way to overcome resistance in ALK+ NSCLC. 🔗 Read the story: alkpositive.org/blog/2024/5/… #DrugRepurposing #ALKPositive

Dr Sofia Merajver, MS, MD, PhD ☮️ avatar
Dr Sofia Merajver, MS, MD, PhD ☮️@sofiamerajver·26 Dec 2024

We still use some of the same drugs my Dad got when I was 15. They are good drugs for other cancers but nor great on lung cancer. We r inventing new drugs, 2b reported soon. #moreresearchmorelife #lcam @UMRogelCancer We want cures! Total elimination or minimal disease

The quest for cancer cures is personal. Like for Dr @sofiamerajver who lost her dad to cancer when she was 15. Its why Dr. Merajver is dedicated to increasing the quality & length of life for ALK+ #lungcancer patients & effecting real cures. #MoreResearchMoreLife #LCAM

Post attachment
ALK Positive avatar
⟳ Dr Sofia Merajver, MS, MD, PhD ☮️ retweeted
ALK Positive@ALKPositiveinc·17 Nov 2024

ALKtALK has the pleasure of hosting Dr. Ignatius Ou this Sunday at 7pm EST. Join us as he discusses using Lorlatinib as first line treatment for his ALK+ patients and what that means for the ALK+ community. Zoom in to be informed and empowered. alkpositive.org/alktalk

Post attachment